Regeneron [REGN] vs Alnylam [ALNY] Detailed Stock Comparison
Regeneron
NASDAQ
Loading...
Alnylam
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Regeneron wins in 14 metrics, Alnylam wins in 4 metrics, with 0 ties. Regeneron appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Regeneron | Alnylam | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 14.41 | -209.81 | Alnylam |
| Price-to-Book Ratio | 1.98 | 236.81 | Regeneron |
| Debt-to-Equity Ratio | 9.04 | 1,093.31 | Regeneron |
| PEG Ratio | -190.96 | -0.72 | Regeneron |
| EV/EBITDA | 11.95 | -487.23 | Alnylam |
| Profit Margin (TTM) | 31.37% | -12.96% | Regeneron |
| Operating Margin (TTM) | 29.64% | -2.09% | Regeneron |
| EBITDA Margin (TTM) | 29.64% | N/A | N/A |
| Return on Equity | 15.34% | -257.83% | Regeneron |
| Return on Assets (TTM) | 6.66% | -2.63% | Regeneron |
| Free Cash Flow (TTM) | $3.54B | $-42.59M | Regeneron |
| Dividend Yield | 0.46% | N/A | N/A |
| 1-Year Return | -40.76% | 72.02% | Alnylam |
| Price-to-Sales Ratio (TTM) | 4.27 | 24.12 | Regeneron |
| Enterprise Value | $53.38B | $60.26B | Alnylam |
| EV/Revenue Ratio | 3.76 | 24.48 | Regeneron |
| Gross Profit Margin (TTM) | 85.58% | 81.52% | Regeneron |
| Revenue per Share (TTM) | $133 | $19 | Regeneron |
| Earnings per Share (Diluted) | $39.48 | $-2.49 | Regeneron |
| Beta (Stock Volatility) | 0.35 | 0.35 | Regeneron |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Regeneron vs Alnylam Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Regeneron | 0.01% | 8.01% | 3.82% | 9.54% | -4.09% | -16.11% |
| Alnylam | 0.07% | 2.54% | 3.13% | 39.79% | 72.77% | 97.32% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Regeneron | -40.76% | -16.94% | -0.34% | 19.07% | 2,029.17% | 6,215.79% |
| Alnylam | 72.02% | 135.43% | 213.60% | 454.34% | 3,521.29% | 4,415.08% |
News Based Sentiment: Regeneron vs Alnylam
Regeneron
News based Sentiment: POSITIVE
Regeneron delivered a strong Q2 earnings report, advanced its pipeline with promising trial results for garetosmab, and secured an FDA label extension for Evkeeza. These positive developments, coupled with continued institutional investment, outweigh the ongoing challenges with legacy Eylea sales, making September a significant month for the company.
Alnylam
News based Sentiment: POSITIVE
October proved to be a strong month for Alnylam, highlighted by a significant milestone payment triggered by the start of a key Phase 3 trial and consistent analyst reports indicating the stock is significantly undervalued. These factors, combined with portfolio diversification efforts, create a positive outlook for the company.
Performance & Financial Health Analysis: Regeneron vs Alnylam
| Metric | REGN | ALNY |
|---|---|---|
| Market Information | ||
| Market Cap | $59.93B | $60.43B |
| Market Cap Category | Large cap | Large cap |
| 10 Day Avg. Volume | 1,067,202 | 969,587 |
| 90 Day Avg. Volume | 998,031 | 1,063,879 |
| Last Close | $600.00 | $460.99 |
| 52 Week Range | $476.49 - $1,045.95 | $205.87 - $484.21 |
| % from 52W High | -42.64% | -4.80% |
| All-Time High | $1,211.20 (Aug 26, 2024) | $484.21 (Sep 09, 2025) |
| % from All-Time High | -50.46% | -4.80% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.04% | 0.17% |
| Quarterly Earnings Growth | -0.03% | 0.17% |
| Financial Health | ||
| Profit Margin (TTM) | 0.31% | -0.13% |
| Operating Margin (TTM) | 0.30% | -0.02% |
| Return on Equity (TTM) | 0.15% | -2.58% |
| Debt to Equity (MRQ) | 9.04 | 1,093.31 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $287.55 | $1.91 |
| Cash per Share (MRQ) | $72.04 | $21.80 |
| Operating Cash Flow (TTM) | $4.74B | $-15,539,000 |
| Levered Free Cash Flow (TTM) | $2.85B | $85.71M |
| Dividends | ||
| Last 12-Month Dividend Yield | 0.46% | N/A |
| Last 12-Month Dividend | $2.64 | N/A |
Valuation & Enterprise Metrics Analysis: Regeneron vs Alnylam
| Metric | REGN | ALNY |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 14.41 | -209.81 |
| Forward P/E | 12.56 | -371.32 |
| PEG Ratio | -190.96 | -0.72 |
| Price to Sales (TTM) | 4.27 | 24.12 |
| Price to Book (MRQ) | 1.98 | 236.81 |
| Market Capitalization | ||
| Market Capitalization | $59.93B | $60.43B |
| Enterprise Value | $53.38B | $60.26B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 3.76 | 24.48 |
| Enterprise to EBITDA | 11.95 | -487.23 |
| Risk & Other Metrics | ||
| Beta | 0.35 | 0.35 |
| Book Value per Share (MRQ) | $287.55 | $1.91 |
Financial Statements Comparison: Regeneron vs Alnylam
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | REGN | ALNY |
|---|---|---|
| Revenue/Sales | $3.03B | $773.69M |
| Cost of Goods Sold | $464.30M | $142.95M |
| Gross Profit | $2.56B | $630.74M |
| Research & Development | $1.34B | $323.62M |
| Operating Income (EBIT) | $591.70M | $-16.20M |
| EBITDA | $900.90M | $35.44M |
| Pre-Tax Income | $905.00M | $-35.36M |
| Income Tax | $96.30M | $30.92M |
| Net Income (Profit) | $808.70M | $-66.28M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | REGN | ALNY |
|---|---|---|
| Cash & Equivalents | $3.09B | $1.02B |
| Total Current Assets | $17.57B | $3.27B |
| Total Current Liabilities | $3.57B | $1.08B |
| Long-Term Debt | $2.70B | $1.26B |
| Total Shareholders Equity | $29.39B | $115.44M |
| Retained Earnings | $32.38B | $-7.35B |
| Property, Plant & Equipment | N/A | $695.92M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | REGN | ALNY |
|---|---|---|
| Operating Cash Flow | $1.36B | $-145.39M |
| Capital Expenditures | N/A | $-8.97M |
| Free Cash Flow | $773.60M | $-127.28M |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | $-1.05B | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | REGN | ALNY |
|---|---|---|
| Shares Short | 2.99M | 3.72M |
| Short Ratio | 3.06 | 3.28 |
| Short % of Float | 0.03% | 0.04% |
| Average Daily Volume (10 Day) | 1,067,202 | 969,587 |
| Average Daily Volume (90 Day) | 998,031 | 1,063,879 |
| Shares Outstanding | 109.62M | 129.29M |
| Float Shares | 97.89M | 126.15M |
| % Held by Insiders | 0.02% | 0.04% |
| % Held by Institutions | 0.90% | 0.99% |
Dividend Analysis & Yield Comparison: Regeneron vs Alnylam
| Metric | REGN | ALNY |
|---|---|---|
| Last 12-Month Dividend | $2.64 | N/A |
| Last 12-Month Dividend Yield | 0.46% | N/A |
| 3-Year Avg Annual Dividend | $0.88 | N/A |
| 3-Year Avg Dividend Yield | 0.14% | N/A |
| 3-Year Total Dividends | $2.64 | N/A |
| Ex-Dividend Date | Aug 18, 2025 | N/A |